Sulforaphane, Gut Health, and Microbiome Research

Summarize human and mechanistic research related to sulforaphane, gut wellness, and the microbiome. Include gut microbes, barrier function, oxidative stress, inflammatory response, metabolites, and conversion efficiency.

Sulforaphane and Gut Wellness

Executive summary

In gut and microbiome research, sulforaphane is connected not only to intake amount but also to conversion. Glucoraphanin must be converted into sulforaphane, and that conversion can depend on plant myrosinase, preparation, and the individual gut microbiome.

Conversion and measurement

Human studies often evaluate sulforaphane exposure through urine or blood markers such as sulforaphane metabolites, sulforaphane-NAC, total dithiocarbamates, or LC-MS/MS-based measurements. Microbial patterns involving Bifidobacterium, Dorea, Ruminococcus torques, Alistipes, and Blautia have been discussed in relation to metabolite excretion.

Human data

Inactive-myrosinase glucoraphanin supplements may produce relatively low bioavailability, while active myrosinase or pre-hydrolyzed sulforaphane can increase exposure. Studies using mustard myrosinase or raw broccoli preparations also support the importance of preparation and enzyme activity.

Gut-wellness interpretation

Human data include signals in IL-6, CRP, and gastric or mucosal oxidative-stress markers. Mechanistic studies connect sulforaphane and glucoraphanin with Nrf2, NF-kB, ERK, occludin, ZO-1, MLCK, cytokines, and epithelial stress responses. Direct human gut-barrier endpoints remain limited.

Individual variation

Genetics, baseline cruciferous intake, preparation, medications such as PPIs, and baseline microbiome may influence response.